Cantrixil is under clinical development by Vivesto and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Cantrixil’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Cantrixil overview

Cantrixil (Trx-1) is under development for the treatment of solid tumors including epithelial ovarian cancer, pancreatic cancer, primary peritoneal cancer and fallopian tube cancer. It is administered intra-peritonealy. Cantrixil is a construct of active drug candidate, TRXE-002, in a cyclodextrin shell. It is based on the super benzopyran drug technology and drug delivery system.

It is also under development for the treatment of ovarian cancer and is administered intravenously.

Vivesto overview

Vivesto, formerly Oasmia Pharmaceutical, is a pharmaceutical company, that develops, manufactures, markets and sells drugs for human and veterinary oncology. The company’s pipeline for human health includes Apealea (paclitaxel micellar) for treating adult patients with the first relapse of platinum-sensitive epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer; Docetaxel micellar, in development for advanced prostate cancer and Cantrixil in clinical development for late-stage ovarian cancer. Its pipeline for animal health includes paccal vet (paclitaxel) and doxophos vet (doxorubicin), currently under phase 2 stage, intended for the treatment of canine mastocytoma and lymphoma. Vivesto also carries out research for the development of next-generation technology platforms XR-18 and XR-19. The company operates through a research facility in Sweden. Vivesto is headquartered in Solna, Stockholm, Sweden.

For a complete picture of Cantrixil’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.